DNA Mismatch Repair and Malaria Drug Resistance

DNA 错配修复和疟疾耐药性

• 批准号: 7649239
• 负责人: Theodore F Taraschi
• 金额: $ 19.3万
• 依托单位: THOMAS JEFFERSON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-07-15 至 2011-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7649239
• 关键词: Ablation; Antimalarials; Biological Assay; Biology; Cells; Cessation of life; Characteristics; DNA; DNA Damage; DNA lesion; Development; Disease; Drug resistance; Drug-sensitive; Gene Mutation; Genome; Genomics; Health; Homologous Gene; Human; In Vitro; Link; MSH3 gene; Malaria; Malignant Neoplasms; Microsatellite Instability; Mismatch Repair; Multi-Drug Resistance; Nuclear; Parasites; Pathway interactions; Pharmaceutical Preparations; Phenotype; Plasmodium; Plasmodium falciparum; Play; Population; Resistance; Role; chemotherapy; in vitro activity; public health relevance; repaired; resistant strain

DESCRIPTION (provided by applicant): The inability of cells to maintain genomic integrity leads to the rapid accumulation of DNA mutations, a scenario that underlies many diseases. In particular, the ablation of DNA mismatch repair (MMR) activity has been linked to several forms of cancer, microsatellite instability, and most notably chemotherapeutic drug resistance. DNA damaging agents used as drug treatments are often associated with a resistance phenotype in cells with decreased MMR activity. Many of the most commonly used antimalarial drugs are DNA altering agents and may play a critical role in the selection of a drug resistant phenotype within the malaria parasite. This resistance may be directly associated with a loss or decrease of MMR activity within parasites. Given Plasmodium falciparum's rapid development of drug resistance and its unusually high A-T rich genome, characteristic of a mutator phenotype, it is not difficult to imagine that the parasite has greatly diminished post-replication repair efficiency. Moreover, the absence of an MSH3 and MSH5 homologue from the Plasmodium genome may allow the persistence of certain types of DNA lesions that would otherwise be removed by the MMR pathway. It is our hypothesis that P. falciparum drug resistant strains have decreased repair of mispaired DNA substrates and that this decreased activity is the underlying mechanism in the development of malaria drug resistance. Efficient MMR plays an indispensable role in determining cellular sensitivity to DNA altering agents. We further hypothesize that current antimalarial drugs, some of which are known DNA altering agents, are selecting for a population of parasites possessing a decreased MMR efficiency. Therefore, we propose to investigate the role that MMR plays in Plasmodium falciparum drug resistance. PUBLIC HEALTH RELEVANCE Human malaria is an enormous global health problem, infecting 300-500 million people, and causing 1-3 million deaths annually. Understanding how Plasmodium falciparum maintains genomic integrity is uncharted territory within malaria biology and may be the key to elucidating the parasites extraordinary adaptability to chemotherapy. It is our hypothesis that P. falciparum drug resistant strains have decreased repair of mispaired DNA substrates and that this decreased activity is the underlying mechanism in the development of malaria drug resistance.

描述（由申请人提供）：细胞无法保持基因组完整性导致DNA突变的快速积累，这是许多疾病的基础。特别是，DNA错配修复（MMR）活性的消除与几种形式的癌症，微卫星不稳定性，最显着的化疗药物耐药性。用作药物治疗的DNA损伤剂通常与具有降低的MMR活性的细胞中的抗性表型相关。许多最常用的抗疟药物是DNA改变剂，可能在疟原虫内抗药性表型的选择中发挥关键作用。这种耐药性可能与寄生虫内MMR活性的丧失或降低直接相关。鉴于恶性疟原虫的耐药性的快速发展及其异常高的A-T丰富的基因组，突变表型的特征，不难想象，寄生虫已大大降低了复制后修复效率。此外，疟原虫基因组中MSH 3和MSH 5同源物的缺失可能允许某些类型的DNA损伤持续存在，否则这些损伤将被MMR途径去除。我们的假设是恶性疟原虫耐药株对错配DNA底物的修复能力降低，这种活性降低是疟疾耐药性发展的潜在机制。有效的MMR在确定细胞对DNA改变剂的敏感性方面起着不可或缺的作用。我们进一步假设，目前的抗疟药物，其中一些是已知的DNA改变剂，选择的寄生虫人口拥有降低MMR效率。因此，我们建议调查的作用，MMR发挥恶性疟原虫耐药性。人类疟疾是一个巨大的全球性健康问题，每年感染3亿至5亿人，造成1至3百万人死亡。了解恶性疟原虫如何保持基因组完整性是疟疾生物学中未知的领域，可能是阐明寄生虫对化疗的非凡适应性的关键。我们的假设是恶性疟原虫耐药株对错配DNA底物的修复能力降低，这种活性降低是疟疾耐药性发展的潜在机制。